NeuroSigma, Inc. is a medical device company based in Westwood, California. NeuroSigma is focused on commercialization of its unique Trigeminal Nerve Stimulation (TNS) technology, and has a growing pipeline of treatments targeting epilepsy, depression, attention deficit hyperactivity disorder (ADHD), and post-traumatic stress disorder (PTSD). NeuroSigma is actively engaged in cutting-edge preclinical research and development, as well as groundbreaking Phase I, II, & III clinical trials.

NeuroSigma, Inc. is a medical device company based in Westwood, California. NeuroSigma is focused on commercialization of its unique Trigeminal Nerve Stimulation (TNS) technology, and has a growing pipeline of treatments targeting epilepsy, depression, attention deficit hyperactivity disorder (ADHD), and post-traumatic stress disorder (PTSD). NeuroSigma is actively engaged in cutting-edge preclinical research and development, as well as groundbreaking Phase I, II, & III clinical trials.

Smileyscope pioneered and patented a powerful new approach to digital therapeutics – virtual reality neuromodulation. 

Smileyscope's innovative therapeutic platform underwent rigorous clinical studies, and has changed pediatric needle practice worldwide. International vascular access guidelines now recommend Smileyscope.

Smileyscope pioneered and patented a powerful new approach to digital therapeutics – virtual reality neuromodulation. Smileyscope's innovative therapeutic platform underwent rigorous clinical studies, and has changed pediatric needle practice worldwide. International vascular access guidelines now recommend Smileyscope. Virtual reality neuromodulation is improving patient and healthcare outcomes. Read on to see how we enhance needle experiences.